Form 8-K - Current report:
SEC Accession No. 0001213900-24-060783
Filing Date
2024-07-12
Accepted
2024-07-12 06:11:24
Documents
14
Period of Report
2024-07-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0209257-8k_elevai.htm   iXBRL 8-K 27843
2 FIRST AMENDMENT TO LICENSE AGREEMENT DATED AS OF JULY 9, 2024, BY AND BETWEEN TH ea020925701ex10-1_elevai.htm EX-10.1 10101
  Complete submission text file 0001213900-24-060783.txt   217254

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE elab-20240709.xsd EX-101.SCH 3033
4 XBRL LABEL FILE elab-20240709_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE elab-20240709_pre.xml EX-101.PRE 22371
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0209257-8k_elevai_htm.xml XML 3805
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

EIN.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241113125
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)